17 patents
Utility
Coronavirus vaccine formulations
3 Jan 23
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines.
Gale Smith, Michael J. Massare, Jing-Hui Tian
Filed: 8 Feb 21
Utility
Modified RSV F proteins and methods of their use
20 Sep 22
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
Filed: 11 Oct 19
Utility
Vaccine compositions having improved stability and immunogenicity
21 Jun 22
Disclosed herein are nanoparticles suitable for use in vaccines.
Gale Smith, Ye Liu, Jing-Hui Tian, Michael J. Massare, Sarathi Boddapati, Erica Shane, Cynthia Oliver, Gregory Glenn
Filed: 21 Nov 17
Utility
Multivalent influenza nanoparticle vaccines
22 Mar 22
Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines.
Sarathi Boddapati, Anushree Herwadkar, Jason Wong, Yen-Huei Lin, Gale Smith, Jing-Hui Tian
Filed: 19 Mar 19
Utility
Vaccine compositions having improved stability and immunogenicity
22 Feb 22
Disclosed herein are nanoparticles suitable for use in vaccines.
Gale Smith, Ye Liu, Jing-Hui Tian, Michael J. Massare, Sarathi Boddapati, Erica Shane, Cynthia Oliver, Gregory Glenn
Filed: 20 Aug 19
Utility
Coronavirus vaccine formulations
22 Feb 22
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines.
Gale Smith, Michael J. Massare, Jing-Hui Tian
Filed: 18 Mar 21
Utility
Methods and compositions for inducing immune responses against Clostridium difficile
21 Sep 21
Disclosed herein are methods and compositions for treating or preventing bacterial infection.
Jing-Hui Tian, Ye Liu, Gale Smith, Gregory Glenn, David Flyer
Filed: 15 Mar 18
Utility
Modified RSV F proteins and methods of their use
6 Jul 21
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
Filed: 15 Jun 18
Utility
Coronavirus vaccine formulations
23 Mar 21
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines.
Gale Smith, Michael J. Massare, Jing-Hui Tian
Filed: 19 Aug 20
Utility
Composition comprising iscom particles and live micro-organisms
26 Oct 20
Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules.
Bror Morein, Karin Lovgren-Bengtsson
Filed: 21 Jan 18
Utility
Immunogenic middle east respiratory syndrome coronavirus (MERS-CoV) compositions and methods
24 Aug 20
Disclosed herein are nanoparticles containing MERS virus proteins in polymer structures, and compositions containing the nanoparticles formulated for administration as immunogenic compositions.
Gale Smith, Ye Liu, Michael Massare
Filed: 18 Sep 14
Utility
Influenza vaccine
10 Aug 20
The present invention relates to a composition comprising at least one ISCOM complex and at least one ectodomain from at least one hemagglutinin (HA) domain and at least one ectodomain from at least one neuraminidase (NA) domain from one or more influenza virus, wherein the extodomains represent ectodomains isolated from the influenza virus.
Albertus D. M. E. Osterhaus, Bror Morein, Karin Lovgren Bengtsson
Filed: 28 Jan 19
Utility
Functional influenza virus like particles (VLPs)
3 Aug 20
The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential.
Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
Filed: 4 Dec 18
Utility
ISCOM preparation and use thereof
3 Aug 20
The invention relates to a composition comprising a mixture of at least two iscom complexes each complex comprising essentially one saponin fraction from Quillaja Saponaria Molina.
Bror Morein, Karin Lövgren Bengtsson
Filed: 30 Dec 14
Utility
Functional influenza virus-like particles (VLPS)
3 Feb 20
The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential.
Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
Filed: 20 Feb 18
Utility
Highly efficient influenza matrix (M1) proteins
27 Jan 20
This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein.
Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
Filed: 21 Mar 18
Utility
Vaccine compositions having improved stability and immunogenicity
30 Sep 19
Disclosed herein are nanoparticles suitable for use in vaccines.
Gale Smith, Ye Liu, Jing-Hui Tian, Michael J. Massare, Sarathi Boddapati, Erica Shane, Cynthia Oliver, Gregory Glenn
Filed: 5 Sep 16
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first